Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism.
作者信息
Packard Chris J
机构信息
From Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.
出版信息
Circulation. 2017 Jan 24;135(4):363-365. doi: 10.1161/CIRCULATIONAHA.116.025897.
Abstract
摘要
相似文献
1
Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism.解析并理解前蛋白转化酶枯草杆菌蛋白酶/克新蛋白酶9型抑制剂对载脂蛋白B代谢的影响
Circulation. 2017 Jan 24;135(4):363-365. doi: 10.1161/CIRCULATIONAHA.116.025897.
2
Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.在葡萄糖代谢受损和 2 型糖尿病患者中，血浆前蛋白转化酶枯草溶菌素 9 没有改变，但它与非高密度脂蛋白胆固醇和载脂蛋白 B 的关系可能会被 2 型糖尿病所改变：CODAM 研究。
Atherosclerosis. 2011 Jul;217(1):263-7. doi: 10.1016/j.atherosclerosis.2011.03.023. Epub 2011 Mar 25.
3
ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.ABO血型与血浆脂质及前蛋白转化酶枯草溶菌素/kexin 9型的关系
Nutr Metab Cardiovasc Dis. 2015 Apr;25(4):411-7. doi: 10.1016/j.numecd.2014.10.015. Epub 2014 Nov 5.
4
Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?超越 LDL：PCSK9 在富含甘油三酯脂蛋白代谢中的作用？
Trends Endocrinol Metab. 2018 Jun;29(6):420-434. doi: 10.1016/j.tem.2018.03.013. Epub 2018 Apr 14.
5
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?前蛋白转化酶枯草杆菌蛋白酶/kexin 9抑制剂：一种新兴的降脂疗法？
J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):157-68. doi: 10.1177/1074248414539562. Epub 2014 Jun 17.
6
Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.关于德卡瓦略等人的评论。前蛋白转化酶枯草杆菌蛋白酶/克新9型（PCSK9）抑制剂与2型糖尿病发病：一项超过96000人年的系统评价和荟萃分析。《糖尿病护理》2018年；41：364 - 367。
Diabetes Care. 2018 Apr;41(4):e69. doi: 10.2337/dc17-2563.
7
Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.对关于德卡瓦略等人的评论的回应。前蛋白转化酶枯草杆菌蛋白酶/克新9型（PCSK9）抑制剂与2型糖尿病发病：一项超过96000人年的系统评价和荟萃分析。《糖尿病护理》2018年；41:364 - 367。
Diabetes Care. 2018 Apr;41(4):e70-e71. doi: 10.2337/dci17-0069.
8
Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.家族性高胆固醇血症患者的前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9 血清水平表明，前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9 通过 LDL 受体非依赖途径从血浆中清除。
Transl Res. 2012 Aug;160(2):125-30. doi: 10.1016/j.trsl.2012.01.010. Epub 2012 Jan 31.
9
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.针对枯草溶菌素转化酶 9 治疗血脂异常和动脉粥样硬化。
J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21.
10
[Gene mutations of proprotein convertase subtilisin/kexin type 9 and low density lipoprotein-cholesterol].[前蛋白转化酶枯草溶菌素/kexin 9型基因突变与低密度脂蛋白胆固醇]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 May 24;45(5):444-446. doi: 10.3760/cma.j.issn.0253-3758.2017.05.018.
引用本文的文献
1
Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.富含甘油三酯脂蛋白相关标志物对冠状动脉疾病患者的预后价值。
J Lipid Res. 2020 Sep;61(9):1254-1262. doi: 10.1194/jlr.RA120000746. Epub 2020 Jul 8.
2
Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias.血脂异常管理中 LDL 胆固醇和“非-HDL”胆固醇的达标影响因素。
Curr Cardiol Rep. 2018 Jun 14;20(8):60. doi: 10.1007/s11886-018-1003-x.
Zotero 插件